Ads
related to: Abbvie
Search results
AbbVie buyout Cerevel marks trial win for Parkinson’s drug
Seeking Alpha· 17 hours agoAbbVie's (ABBV) buyout target, Cerevel Therapeutics (CERE), announced positive data for its...
Heard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Better
The Wall Street Journal· 12 hours agoAbbVie’s acquisition of neuroscience biotech Cerevel Therapeutics hasn’t closed yet. Notably, when ...
AbbVie stock gains as Rinvoq succeeds in giant cell arteritis
Seeking Alpha· 14 hours agoAbbVie (ABBV) stock gains as the company's JAK inhibitor, upadacitinib, succeeds in a Phase 3 trial...
AbbVie-bound Cerevel reports phase 3 Parkinson's victory in early win for $8.7B deal
FierceBiotech· 15 hours agoThe backing singer in AbbVie’s $8.7 billion takeover of Cerevel Therapeutics is having its moment in...
Counterfeit Botox linked to illnesses in nine states
The Independent US via AOL· 13 hours agoCounterfeit Botox shares similarities to the FDA-approved Botox manufactured by AbbVie. However, Botox made by AbbVie displays their product description...
AbbVie's Upadacitinib shows promise in giant cell arteritis study By Investing.com
Investing.com· 12 hours agoThe study met both its primary endpoint and key secondary endpoints, with a higher percentage of...
AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
Zacks via Yahoo Finance· 1 day agoThe latest trading session saw AbbVie (ABBV) ending at $164.25, denoting a +1.05% adjustment from...
AbbVie Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointment (ABBV)
Seeking Alpha· 10 hours agoAnalyst’s Disclosure: I/we have a beneficial long position in the shares of ABBV either through...
Abbvie Inc [ABBV] Shares Rise 1.05 % on Wednesday – Knox Daily
Knox Daily· 21 hours agoInvestors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Abbvie Inc shares valued at $3,716,757 were sold by Donoghoe ...
AbbVie Study on Treatment for Giant Cell Arteritis Meets Primary Endpoint
Morningstar· 14 hours agoBy Denny Jacob AbbVie disclosed positive top-line results from a study on upadacitinib to treat adults with giant cell arteritis, an autoimmune disease. The drugmaker said ...
